When orally administrated with EcN and EcN‐GLP‐1, the level of colon inflammation dropped significantly compared to that of exenatide, which means that the better therapeutic effects might benefit more from the probiotic properties of EcN.35, 39. The gene discussed is GLP1R; the disease is digestive system cancer.